.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
QuintilesIMS
Queensland Health
Fish and Richardson
Covington
Daiichi Sankyo
Farmers Insurance
Harvard Business School
Chinese Patent Office
Cerilliant

Generated: December 15, 2017

DrugPatentWatch Database Preview

NUPLAZID Drug Profile

« Back to Dashboard

Which patents cover Nuplazid, and when can generic versions of Nuplazid launch?

Nuplazid is a drug marketed by Acadia Pharms Inc and is included in one NDA. There are fourteen patents protecting this drug.

This drug has one hundred and forty-two patent family members in twenty-seven countries.

The generic ingredient in NUPLAZID is pimavanserin tartrate. One supplier is listed for this compound. Additional details are available on the pimavanserin tartrate profile page.

Summary for NUPLAZID

Drug patent expirations by year for NUPLAZID

Pharmacology for NUPLAZID

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Acadia Pharms IncNUPLAZIDpimavanserin tartrateTABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Acadia Pharms IncNUPLAZIDpimavanserin tartrateTABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Acadia Pharms IncNUPLAZIDpimavanserin tartrateTABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Acadia Pharms IncNUPLAZIDpimavanserin tartrateTABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Acadia Pharms IncNUPLAZIDpimavanserin tartrateTABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Acadia Pharms IncNUPLAZIDpimavanserin tartrateTABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Acadia Pharms IncNUPLAZIDpimavanserin tartrateTABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Acadia Pharms IncNUPLAZIDpimavanserin tartrateTABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Acadia Pharms IncNUPLAZIDpimavanserin tartrateTABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Acadia Pharms IncNUPLAZIDpimavanserin tartrateTABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: NUPLAZID

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,868,176Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-y1)-N'-(4-(2-methylprop- yloxy)phenylmethyl)carbamide and their preparation► Subscribe
8,008,323Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
2,017,165,273► Subscribe
8,227,487Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
7,790,899Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)ph- enylmethyl)carbamide and its tartrate salt and crystalline forms► Subscribe
8,377,959Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
7,994,193Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
7,713,995Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
9,211,289Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
7,732,462Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: NUPLAZID

Country Document Number Estimated Expiration
South Africa200505680► Subscribe
Austria407117► Subscribe
Russian Federation2266282► Subscribe
Mexico2007003433► Subscribe
China1443167► Subscribe
Singapore161221► Subscribe
China102153505► Subscribe
Cyprus1118651► Subscribe
World Intellectual Property Organization (WIPO)2004064738► Subscribe
Spain2310529► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Federal Trade Commission
Queensland Health
QuintilesIMS
Cipla
Boehringer Ingelheim
Chubb
Fuji
Medtronic
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot